ClinicalTrialsFinder

Ovarian Cancer Recurrent Clinical Trials in Changsha, Hunan

1 recruitingChangsha, Hunan, China

Showing 1–1 of 1 trials

Recruiting
Early Phase 1

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Ovarian Cancer Recurrent
Second Xiangya Hospital of Central South University5 enrolled1 locationNCT06660511